Stockwinners Market Radar for March 10, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
PHG | Hot Stocks20:40 EDT Philips says instant wave-free ratio more cost-effective in study - Royal Philips announced health economic results from the Define Flair clinical trial comparing cost-effectiveness between instant wave-free ratio and fractional flow reserve in the guidance of treatment of ischemic heart disease at the American College of Cardiology annual meeting. The study found that an iFR-guided strategy offers a one-year average cost savings of $896 per patient compared to an FFR-guided strategy, while delivering consistent patient outcomes, Philips says. iFR "is an innovative pressure-derived index unique to Philips, a global leader in image-guided therapy solutions, allowing a simplified hyperemia-free physiological assessment of coronary blockages," it added.
|
MDT | Hot Stocks20:38 EDT Medtronic announces results from CoreValve U.S. Pivotal Extreme Risk Study - Medtronic announced outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world Notion trial, both of which examined patients with the CoreValvetrans catheter aortic valve replacement system at five years post-implant. Results from the studies demonstrated that patients implanted with the CoreValve TAVR system showed "strong hemodynamic performance and improved quality of life out to five years," the company said, The physician-initiated trial studied an all-comers population of 280 patients at least 70 years old who were randomized to surgical or transcatheter aortic valve replacement using the CoreValve System. Results at five-year follow-up showed similar rates of all-cause mortality and superior hemodynamic performance for TAVR compared to surgery, Medtronic added. Also presented were the final five-year results from the CoreValve U.S. Pivotal Extreme Risk Study, which enrolled the first US IDE cohort of patients ever to be treated with the self-expanding CoreValve TAVR system. Results from the study continued to show positive outcomes at five years for the surviving patients - all of whom were deemed to be facing considerable harm or mortality with a surgical valve replacement, according to Medtronic. Patients implanted with the CoreValve system maintained a notable improvement in quality of life and sustained low mean gradients.
|
IRTC | Hot Stocks20:22 EDT iRhythm says Zio improved atrial fibrillation detection in study - iRhythm Technologies announced primary results of the mHealth Screening to Prevent Strokes study that evaluated detection of silent atrial fibrillation in high-risk individuals using Zio by iRhythm. Electrocardiogram recording and analysis were carried out using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. After four months, the new incidence of AF was 5.1% among patients who were immediately monitored with the Zio Service compared with 0.6% in patients who were assigned to a delayed monitoring group and had not yet worn the Zio monitor. At one year, primary results showed that AF was newly diagnosed in 6.3% of patients who were actively monitored by the Zio service versus 2.3% in the observational control group receiving routine care. In addition, 4.0% of patients in the Zio monitored group were found to have potentially actionable arrhythmias other than AF including ventricular tachycardia, pause, AV block, and symptomatic supraventricular tachycardia. iRhythm added, "Monitoring with Zio led to significant change in clinical treatment of the actively monitored group including initiation of anticoagulation therapies (5.4%), antiarrhythmic medications (0.8%), and pacemaker placement (0.7%). Patients receiving anticoagulation for AF appeared to fulfill current clinical guidelines for appropriateness and need. Mean wear time for the Zio patch was 12 days with 98% analyzable ECG data." The study involved 5214 eligible Aetna members who were identified through claims data to have risk factors for AF but had not been previously diagnosed. 1738 individuals were enrolled via a web-based platform to undergo either immediate or delayed active ECG monitoring at home for up to 4 weeks with a Zio XT patch monitor. Each monitored participant was matched with two non-monitored participants with a similar CHA2DS2-VASc, a standardized stroke-risk assessment score, to act as controls. The study looked at time to first diagnosis of AF and its clinical consequences for the active monitoring cohort as well as the cohort undergoing usual care.
|
REGN SNY | Hot Stocks09:06 EDT Regeneron, Sanofi say Odyssey Outcomes trial met primary endpoint - Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the Odyssey Outcomes trial met its primary endpoint, showing Praluent Injection "significantly reduced" the risk of major adverse cardiovascular events in patients who had suffered a recent acute coronary syndrome event, such as a heart attack. Results from the trial will be presented today during a late-breaker session at the American College of Cardiology's Scientific Session in Orlando, Florida. Key findings include: On the primary endpoint, Praluent reduced the overall risk of MACE by 15%. The MACE composite endpoint includes patients who experienced a heart attack, ischemic stroke, death from coronary heart disease, or unstable angina requiring hospitalization; Praluent was also associated with a lower risk of death overall, known as "all-cause mortality", and there were also numerically fewer CHD deaths; In a pre-specified analysis, the patients with baseline LDL-C levels at or above 100 mg/dL experienced a more pronounced effect from Praluent, reducing their risk of MACE by 24%. "This trial was consistent with earlier statin trials, showing the greatest benefit in patients with higher cholesterol levels at baseline," said George Yancopoulos, MD, PhD, President and Chief Scientific Officer, Regeneron. "Many patients who have survived a recent heart attack or other coronary event are unable to reach an LDL cholesterol goal of less than 100 mg/dL, and have an urgent need for new therapeutic options because of their increased risk of another event. In this trial, such patients who received Praluent on top of maximally-tolerated statins had important reductions in their risk."
|
WYNN | Hot Stocks07:39 EDT Wynn Resorts enters into funding commitment letter with Deutsche Bank - Wynn Resorts announced last night that it has entered into a commitment letter with Deutsche Bank for a 364-day term loan facility to the company in an aggregate principal amount of up to $800M. If utilized, the company intends to use the net proceeds of this committed financing, and cash on hand, to repay the promissory note that the company previously issued to Aruze USA.
|
QVCA | Hot Stocks07:38 EDT Liberty Interactive, GCI Liberty announce completion of transactions - Liberty Interactive (QVCA) and GCI Liberty (GLIBA, GLIBP) announced the completion of Liberty's previously announced acquisition of GCI Liberty and series of transactions that effected the split-off of GCI Liberty. As a result of the transactions, LIC no longer holds an equity interest in GCI Liberty. Following the split-off, there are approximately 105M shares of GLIBA, 4.5M shares of GLIBB, and 7.3M shares of GLIBP outstanding, and former Liberty Ventures stockholders hold approximately 79% of the common equity of GCI Liberty and an approximate 83% voting interest in GCI Liberty based on shares outstanding as of closing. After giving effect to the transactions, the cash balance at GCI Liberty is approximately $466M.
|
TSLA... | Hot Stocks06:22 EDT Week in review: How Trump's policies moved stocks - Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump and his administration with this weekly recap compiled by The Fly: 1. TARIFFS ON STEEL, ALUMINUM: President Trump signed a proclamation on Thursday imposing a 25% tariff on steel imports and a 10% tariff on aluminum imports from all foreign countries, with the exception of Canada and Mexico for now while NAFTA negotiations are underway. The day before, House Republicans had signed a letter to the White House expressing "deep concern" over the potential tariffs. On Thursday, Politico reported that the GOP may block President Trump's tariffs proposal, as Senator Jeff Flake was expected to introduce legislation to nullify the proposal. Publicly traded metal producers include U.S. Steel (X), Century Aluminum (CENX), Alcoa (AA), and AK Steel (AKS). 2. NAMES VULNERABLE TO TRADE RETALIATION: The President's tariffs on aluminum and steel imports have elicited a number of negative reviews from corporate America. For instance, late last week the chair of the National Association of Home Builders, or NAHB, Randy Noel said: "These tariffs will translate into higher costs for consumers and U.S. businesses that use these products, including home builders." That sentiment was shared by Best Buy (BBY) CEO Hubert Joly and the CFO of Home Depot (HD), who both see tariffs as potentially harmful. Meanwhile, Exxon Mobil (XOM) chairman and CEO Darren Woods told CNBC that the news threatens to undo some of the improvements business saw from the administration's tax reform and deregulation efforts. Shares of U.S.-based auto manufacturers Ford (F) and General Motors (GM) could be hurt by higher input costs from steel. Machinery makers Terex (TEX), Oshkosh (OSK), Deere (DE) and Caterpillar (CAT) may also feel the squeeze as input costs rise. 3. CHINA TARIFF THREATS: Chinese manufacturers that supply U.S. multinationals from Walmart (WMT) to Nike (NKE) may be hit by potential tariffs being considered by President Donald Trump creating a ripple effect into American brands, Bloomberg reported earlier this week, citing Chinese manufacturers. Trump is weighing tariffs on imports ranging from shoes and clothing to consumer electronics, putting Chinese companies like Yue Yuen Industrial Holdings, which supplies Nike and Under Armour (UA, UAA), and Li & Fung (LFUGF), which has Walmart and Macy's (M) as customers, on the hook. 4. CHINA/U.S. CAR RULES: Earlier this week, Tesla (TSLA) CEO Elon Musk tweeted President Donald Trump saying, "Do you think the US & China should have equal & fair rules for cars? Meaning, same import duties, ownership constraints & other factors....For example, an American car going to China pays 25% import duty, but a Chinese car coming to the US only pays 2.5%, a tenfold difference...Also, no US auto company is allowed to own even 50% of their own factory in China, but there are five 100% China-owned EV auto companies in the US." Musk was responding to Trump's prior tweet that said, "China has been asked to develop a plan for the year of a One Billion Dollar reduction in their massive Trade Deficit with the United States. Our relationship with China has been a very good one, and we look forward to seeing what ideas they come back with. We must act soon!" 5. EV TAX CREDIT: General Motors CEO Mary Barra urged Washington to expand electric-vehicle tax credit, a plea that would help the company and peers such as Tesla sell battery-powered vehicles, the Wall Street Journal reported on Wednesday. Certain car makers face the expiration of $7,500 income-tax credit that has applied to hundreds of thousands of electric car purchases since the Obama administration first began offering the credit, the report noted. 6. VIDEOGAMES: President Donald Trump met with several leaders of the video game industry on Thursday to discuss the potential role video game violence may have played in events such as the Parkland school shooting last month. Publicly traded companies in the space include Activision Blizzard (ATVI), Electronic Arts (EA), Take-Two (TTWO), GameStop (GME), and Nintendo (NTDOY). "Week in Review" is The Fly's weekly recap of its recurring series of "Trump Effect" exclusive stories.
|